BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 35849791)

  • 21. [Pharmacological and clinical profile of gilteritinib (Xospata
    Mori M; Hidaka K
    Nihon Yakurigaku Zasshi; 2021; 156(1):37-46. PubMed ID: 33390479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Zucenka A; Griskevicius L
    Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.
    McMahon CM; Perl AE
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):841-849. PubMed ID: 31454267
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness of gilteritinib for relapsed/refractory
    Pandya BJ; Qi CZ; Garnham A; Yang H; Shah MV; Zeidan AM
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1469-1481. PubMed ID: 34595955
    [No Abstract]   [Full Text] [Related]  

  • 26. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
    Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
    Leuk Lymphoma; 2023 Jan; 64(1):188-196. PubMed ID: 36287540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
    Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
    Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
    Bewersdorf JP; Shallis RM; Derkach A; Goldberg AD; Stein A; Stein EM; Marcucci G; Zeidan AM; Shimony S; DeAngelo DJ; Stone RM; Aldoss I; Ball BJ; Stahl M
    Leuk Res; 2022 Nov; 122():106942. PubMed ID: 36108424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
    Daver N; Venugopal S; Ravandi F
    Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Récher C; Yoon SS; Hosono N; Onozawa M; Chiba S; Kim HJ; Hasabou N; Lu Q; Tiu R; Levis MJ
    Blood; 2022 Jun; 139(23):3366-3375. PubMed ID: 35081255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel approach for relapsed/refractory FLT3
    Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
    Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Ngo D; Tinajero J; Li S; Palmer J; Pourhassan H; Aribi A; Nakamura R; Stein A; Marcucci G; Salhotra A; Sandhu K; Pullarkat V; Ball B; Koller P
    Leuk Lymphoma; 2024 Mar; 65(3):372-377. PubMed ID: 38164785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan.
    Sugamori H; Lee T; Mitomi T; Yamagishi C
    Jpn J Clin Oncol; 2022 Jul; 52(7):766-773. PubMed ID: 35523692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
    Konopleva M; Thirman MJ; Pratz KW; Garcia JS; Recher C; Pullarkat V; Kantarjian HM; DiNardo CD; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Wei AH
    Clin Cancer Res; 2022 Jul; 28(13):2744-2752. PubMed ID: 35063965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
    Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
    Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a
    Pulte ED; Norsworthy KJ; Wang Y; Xu Q; Qosa H; Gudi R; Przepiorka D; Fu W; Okusanya OO; Goldberg KB; De Claro RA; Farrell AT; Pazdur R
    Clin Cancer Res; 2021 Jul; 27(13):3515-3521. PubMed ID: 33632926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia.
    Kang C; Blair HA
    Target Oncol; 2020 Oct; 15(5):681-689. PubMed ID: 32940858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.